Search Results

You are looking at 41 - 50 of 295 items for :

Clear All
Full access

Kohei Shitara and Atsushi Ohtsu

overall survival (OS) of 10 to 15 months. 1 – 4 The survival benefit of second-line therapy has recently been confirmed in several randomized trials. 5 – 7 Regarding molecular targeting agents, trastuzumab, a monoclonal antibody against HER2

Full access

William J. Gradishar

treatment of metastatic HER2-positive disease. Newer Strategies for Overcoming Endocrine Resistance The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer recommend treating recurrent invasive breast cancer showing

Full access

Fiona Tsui-Fen Cheng, Fu Ou-Yang, Nina Lapke, Kai-Che Tung, Yen-Kung Chen, Yuh-Yu Chou and Shu-Jen Chen

receptor–positive, progesterone receptor–negative, and HER2-negative (HER2−), and had spread to 10 of 17 dissected lymph nodes. The patient was treated with TEC (taxotere, epirubicin, and cyclophosphamide) adjuvant chemotherapy for 3.5 months followed by

Full access

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns and Rashmi Kumar

epidermal growth factor receptor 2 (HER2) overexpression, tumor burden, and patient preference are important factors in selecting appropriate therapeutic strategy for patients with recurrent/stage IV disease. These guidelines have been developed by the NCCN

Full access

Sharon H. Giordano, Anthony D. Elias and William J. Gradishar

University of Texas MD Anderson Cancer Center, described treatments for patients with HER2-positive cancer. Anthony D. Elias, MD, Professor of Medicine, and the Martha Cannon Dear Chair in Breast Cancer Research, University of Colorado Cancer Center

Full access

Elena Elimova, Roopma Wadhwa, Hironori Shiozaki, Kazuki Sudo, Jeannelyn S. Estrella, Brian D. Badgwell, Prajnan Das, Aurelio Matamoros Jr, Shumei Song and Jaffer A. Ajani

treatment options, is needed and is the basis for this review. Currently, only 2 molecular subtypes have been identified that are relevant in the clinic. This is based on the overexpression of HER2 protein and/or the amplification of its gene ERBB2 , thus

Full access

Helena A. Yu and Gregory J. Riely

Epidermal Growth Factor Receptors The epidermal growth factor receptor (EGFR) family includes 4 receptor tyrosine kinases: EGFR (HER1), ERBB2 (HER2), ERBB3 (HER3), and ERBB4 (HER4). The EGFR is composed of an extracellular ligand binding

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead and Rashmi Kumar

(T-DM1) for patients with HER2-positive metastatic breast cancer. Principles of Preoperative Systemic Therapy The NCCN Breast Cancer Panel has outlined the rationale, appropriate patient selection, and response assessment for preoperative

Full access

Jaffer A. Ajani, David J. Bentrem, Stephen Besh, Thomas A. D’Amico, Prajnan Das, Crystal Denlinger, Marwan G. Fakih, Charles S. Fuchs, Hans Gerdes, Robert E. Glasgow, James A. Hayman, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, A. Craig Lockhart, Kenneth Meredith, Mary F. Mulcahy, Mark B. Orringer, James A. Posey, Aaron R. Sasson, Walter J. Scott, Vivian E. Strong, Thomas K. Varghese Jr, Graham Warren, Mary Kay Washington, Christopher Willett, Cameron D. Wright, Nicole R. McMillian and Hema Sundar

: Describe the postoperative treatment options for patients with resectable gastric cancer. Discuss the role of HER-2 testing and trastuzumab for patients with metastatic cancer. NCCN Guidelines Insights : Gastric Cancer, Version 2.2013 Version 2

Full access

Jaffer A. Ajani, Thomas A. D'Amico, Khaldoun Almhanna, David J. Bentrem, Joseph Chao, Prajnan Das, Crystal S. Denlinger, Paul Fanta, Farhood Farjah, Charles S. Fuchs, Hans Gerdes, Michael Gibson, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kimberly L. Johung, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, Stephen Leong, Catherine Linn, A. Craig Lockhart, Quan P. Ly, Mary F. Mulcahy, Mark B. Orringer, Kyle A. Perry, George A. Poultsides, Walter J. Scott, Vivian E. Strong, Mary Kay Washington, Benny Weksler, Christopher G. Willett, Cameron D. Wright, Debra Zelman, Nicole McMillian and Hema Sundar

HER2 overexpression, systemic therapy for locally advanced or metastatic disease, and best supportive care for the prevention and management of symptoms due to advanced disease. Staging Two major classifications are currently being used. The